PA
SGTX

Perceptive Advisors’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Perceptive Advisors’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,615
Closed -$1.34M – 163
2021
Q2 		$1.34M Hold
9,615
– – 0.02% 139
2021
Q1 		$2.79M Hold
9,615
– – 0.04% 123
2020
Q4 		$6M Buy
+9,615
New +$4.36M 0.06% 116

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Perceptive Advisors's SGTX Position: Q3 2021 in Review

Perceptive Advisors sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2021, closing a stake of 9,615 shares — an estimated $1.34M sold.

Perceptive Advisors first reported a position in SGTX in Q4 2020 and held it in 3 quarters. The position peaked at $6M in Q4 2020. 45 funds tracked by Wall St. Rank hold SGTX as of Q3 2021.

  • Perceptive Advisors reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Perceptive Advisors sold 9,615 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.34M.
  • Perceptive Advisors first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Perceptive Advisors's Sigilon Therapeutics, Inc. Common Stock position peaked at $6M in Q4 2020.
  • 45 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.